Selective Inhibition of Bromodomain-Containing Protein 4 Reduces Myofibroblast Transdifferentiation and Pulmonary Fibrosis.

Frontiers in molecular medicine Pub Date : 2022-01-01 Epub Date: 2022-03-15 DOI:10.3389/fmmed.2022.842558
Ksenija Bernau, Melissa Skibba, Jonathan P Leet, Sierra Furey, Carson Gehl, Yi Li, Jia Zhou, Nathan Sandbo, Allan R Brasier
{"title":"Selective Inhibition of Bromodomain-Containing Protein 4 Reduces Myofibroblast Transdifferentiation and Pulmonary Fibrosis.","authors":"Ksenija Bernau,&nbsp;Melissa Skibba,&nbsp;Jonathan P Leet,&nbsp;Sierra Furey,&nbsp;Carson Gehl,&nbsp;Yi Li,&nbsp;Jia Zhou,&nbsp;Nathan Sandbo,&nbsp;Allan R Brasier","doi":"10.3389/fmmed.2022.842558","DOIUrl":null,"url":null,"abstract":"<p><p>Idiopathic pulmonary fibrosis is a lethal disease driven by myofibroblast expansion. Currently no therapies exist that target the epigenetic mechanisms controlling myofibroblast transdifferentiation, which is responsible for unregulated extracellular matrix (ECM) production. We have recently shown that bromodomain-containing protein 4 (BRD4), an epigenetic regulator that forms a scaffold for nuclear activators and transcription factors, is essential for TGFβ-induced myofibroblast transdifferentiation. However, its role in the development and progression of pulmonary fibrosis <i>in vivo</i> has not been established. Here, we evaluate the hypothesis that BRD4 bromodomain interactions mediate myofibroblast expansion and fibrosing disease <i>in vivo</i>. C57BL/6J mice challenged with intratracheal bleomycin were systemically treated with a selective allosteric inhibitor of the BRD4 bromodomain 1 (BD1), ZL0591 (10 mg/kg), during the established fibrotic phase (14 days post-bleomycin) in a rigorous therapeutic paradigm. Eleven days after initiation of ZL0591 treatment (25 days post-bleomycin), we detected a significant improvement in blood O<sub>2</sub> saturation compared to bleomycin/vehicle control. Twenty-eight days post-bleomycin, we observed a reduction in the volumetric Hounsfield Unit (HU) density by micro computed tomography (μCT) in the ZL0591-treated group, as well as a reduction in collagen deposition (hydroxyproline content) and severity of injury (Ashcroft scoring). Myofibroblast transdifferentiation was measured by smooth muscle α-actin (αSMA) staining, indicating a loss of this cell population in the ZL0591-treated group, and corresponded to reduced transcript levels of myofibroblast-associated extracellular matrix genes, tenascin-C and collagen 1α1. We conclude that BRD4 BD1 interactions are critical for myofibroblast transdifferentiation and fibrotic progression in a mouse model of pulmonary fibrosis.</p>","PeriodicalId":73090,"journal":{"name":"Frontiers in molecular medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245900/pdf/","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in molecular medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fmmed.2022.842558","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/3/15 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Idiopathic pulmonary fibrosis is a lethal disease driven by myofibroblast expansion. Currently no therapies exist that target the epigenetic mechanisms controlling myofibroblast transdifferentiation, which is responsible for unregulated extracellular matrix (ECM) production. We have recently shown that bromodomain-containing protein 4 (BRD4), an epigenetic regulator that forms a scaffold for nuclear activators and transcription factors, is essential for TGFβ-induced myofibroblast transdifferentiation. However, its role in the development and progression of pulmonary fibrosis in vivo has not been established. Here, we evaluate the hypothesis that BRD4 bromodomain interactions mediate myofibroblast expansion and fibrosing disease in vivo. C57BL/6J mice challenged with intratracheal bleomycin were systemically treated with a selective allosteric inhibitor of the BRD4 bromodomain 1 (BD1), ZL0591 (10 mg/kg), during the established fibrotic phase (14 days post-bleomycin) in a rigorous therapeutic paradigm. Eleven days after initiation of ZL0591 treatment (25 days post-bleomycin), we detected a significant improvement in blood O2 saturation compared to bleomycin/vehicle control. Twenty-eight days post-bleomycin, we observed a reduction in the volumetric Hounsfield Unit (HU) density by micro computed tomography (μCT) in the ZL0591-treated group, as well as a reduction in collagen deposition (hydroxyproline content) and severity of injury (Ashcroft scoring). Myofibroblast transdifferentiation was measured by smooth muscle α-actin (αSMA) staining, indicating a loss of this cell population in the ZL0591-treated group, and corresponded to reduced transcript levels of myofibroblast-associated extracellular matrix genes, tenascin-C and collagen 1α1. We conclude that BRD4 BD1 interactions are critical for myofibroblast transdifferentiation and fibrotic progression in a mouse model of pulmonary fibrosis.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
选择性抑制含溴结构域蛋白4减少肌成纤维细胞转分化和肺纤维化。
特发性肺纤维化是一种由肌成纤维细胞扩张引起的致死性疾病。目前还没有针对控制肌成纤维细胞转分化的表观遗传机制的治疗方法,而肌成纤维细胞转分化是细胞外基质(ECM)产生不调节的原因。我们最近发现,含溴结构域蛋白4 (BRD4)是一种表观遗传调节剂,可形成核激活因子和转录因子的支架,对tgf β诱导的肌成纤维细胞转分化至关重要。然而,其在体内肺纤维化发生和进展中的作用尚未确定。在这里,我们评估了BRD4溴结构域相互作用在体内介导肌成纤维细胞扩张和纤维化疾病的假设。在确定的纤维化期(博来霉素后14天),用气管内博来霉素刺激C57BL/6J小鼠,系统地使用BRD4溴结构域1 (BD1)的选择性变抗抑制剂ZL0591 (10 mg/kg)进行治疗。在ZL0591治疗开始11天后(博来霉素治疗后25天),我们检测到与博来霉素/对照相比,血氧饱和度有显著改善。博莱霉素治疗28天后,我们观察到zl0591治疗组的体积Hounsfield单位(HU)密度(μCT)降低,胶原沉积(羟脯氨酸含量)和损伤严重程度(Ashcroft评分)减少。平滑肌α-肌动蛋白(αSMA)染色检测了肌成纤维细胞的转分化,表明在zl0591处理组中,该细胞群的缺失,与肌成纤维细胞相关的细胞外基质基因、腱蛋白c和胶原蛋白1α1的转录水平降低相对应。我们得出结论,在肺纤维化小鼠模型中,BRD4 - BD1相互作用对肌成纤维细胞转分化和纤维化进展至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Editorial: Gene therapy and genome editing for metabolic liver disorders. An artificial transcription factor that activates potent interferon-γ expression in human Jurkat T Cells. Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model. Human-specific gene ARHGAP11B-potentially an additional tool in the treatment of neurodegenerative diseases? DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1